Search Results for “EC” – Page 163 – media

FDA Approves Genentech’s Alecensa Lung Cancer Treatment

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Alecensa (alectinib) for the treatment of people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
- Source: Pharmpro
- 598
- November 9, 2017
ALK FDA New Approvals NSCLC sNDA
FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN

Cellectis (Alternext: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold, previously announced on September 4, 2017, on Phase 1 trials of Cellectis’ UCART123 product candidate in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
- Source: Cellectis
- 562
- November 9, 2017
Cellectis Clinical Trials FDA immunotherapies UCART
EU OKs low-dose Xarelto to prevent recurrent VTE

A lower dose formulation of Bayer and Janssen’s bloodthinner Xarelto has been approved by European regulators for preventing recurrent venous thromboembolism, expanding treatment options for patients.
- Source: Pharmatimes
- 618
- November 8, 2017
cardiovascular New Approvals venous thromboembolism VTE
Cancer cells destroyed in just 3 days with new technique

Cancer cells are relentless, possessing the vexatious ability to develop resistance to current therapies and making the disease hugely challenging to treat. However, an exciting new study may have identified cancer's weak spot; the discovery has already led to the near-eradication of the disease in cell cultures.
- Source: medicalnewstoday
- 671
- November 8, 2017
cancer cell chromatin Researches
Moderna Announces New Collaboration with AstraZeneca

Moderna Therapeutics today announced a new license and collaboration with AstraZeneca to co-develop and co-commercialize a messenger RNA (mRNA) therapeutic encoding for Relaxin. The companies will advance the new Relaxin development candidate, AZD7970, toward the clinic as an investigational treatment for heart failure.
- Source: Modernatx
- 460
- November 7, 2017
heart Market Views mRNA
‘Precision Medicine’ may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the world's more diverse populations, according to a study led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and the Keck School of Medicine of the University of Southern California (USC).
- Source: worldpharmanews
- 543
- November 6, 2017
cancer oncology precision medicine Researches
Four-in-one flu shot may mean lifelong protection against the flu

A vaccine combining centralized ancestral genes from four major influenza strains appears to provide broad protection against the dangerous ailment, according to new research by a team from the Nebraska Center for Virology.
- Source: Medicalxpress
- 726
- November 3, 2017
gene influenza strains Researches vaccine
GSK’s investigational BCMA antibody-drug conjugate receives Breakthrough Therapy Designation from US FDA for relapsed and refractory multiple myeloma

In October, the European Medicines Agency (EMA) granted PRIME designation to GSK2857916 for the treatment of relapsed and refractory multiple myeloma patients whose prior therapy included a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody. GSK2857916 is an anti B-cell maturation agent (BCMA) monoclonal antibody-drug conjugate.
- Source: gsk
- 552
- November 3, 2017
inhibitor multiple myeloma New Approvals refractory relapsed
Bristol-Myers, J&J sink cash into a new $95M European biotech fund

A venture capital firm in the Netherlands — backed by some big names in Big Pharma — has raised $95 million in a new fund to fuel European biotech startups.
- Source: Endpts
- 610
- November 3, 2017
diagnostics funding Market Views medical device therapeutics
Cancer-detecting start-up Grail is seeking more funding, mere months after raising $900 million

Grail, the cancer detection start-up backed by tech giants Alphabet and Amazon, is already seeking new funding, mere months after it closed a $900 million round in March. The company had previously raised $100 million in 2016.
- Source: Cnbc
- 458
- November 2, 2017
cancer detection funding Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.